Document is current
Any future updates will be listed below
-
Authors
Muqaku, Besnik
Anderl-Straub, Sarah
Werner, Leonie
Nagl, Magdalena
Otto, Markus
Teunissen, Charlotte E.
Oeckl, Patrick https://orcid.org/0000-0002-7652-7023
-
Funding
Funding for this research was provided by:
Alzheimer Forschung Initiative (20059CB)
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
- License Information
-
More Information
Article History
Received: 16 July 2024
Revised: 4 September 2024
Accepted: 8 September 2024
First Online: 25 September 2024
Declarations
:
: PO received research support from the ALS Association (24-SGP-691, 23-PPG-674–2), ALS Finding a Cure, the Charcot Foundation, the DZNE Innovation-to-Application program and consulting fees from LifeArc and Fundamental Pharma. PO and MO received support from the Cure Alzheimer Fund. MO received research support from German Federal Ministry of Education and Research (FTLDc 01GI1007A), the EU Joint Programme-Neurodegenerative Diseases networks Genfi-Prox (01ED2008A), the EU (MOODMARKER 01EW2008), the German Research Foundation/DFG (SFB1279), the foundation of the state Baden-Württemberg (D.3830), Boehringer Ingelheim Ulm University BioCenter (D.5009), and the Thierry Latran Foundation.
: The Ethics Committee of Ulm University approved the study (approval no. 20/10).
: All patients gave written informed consent to be included in the study.
